Effect of Light Emitting Diode Therapy on Muscle Fatigue

NCT ID: NCT04367727

Last Updated: 2020-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-01

Study Completion Date

2021-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the optimal time interval between light emitting diode application and exercise to improve fatigue resistance.The results of this study could be useful in planning a rehabilitation program in musculature disorders and also in athletic training.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. To determine the effect of light emitting diode applied 5 minutes before exercise on pain, rate of perceived exertion and maximum voluntary contraction.
2. To determine the effect of light emitting diode applied 1 hour before exercise on pain, rate of perceived exertion and maximum voluntary contraction.
3. To determine the effect of light emitting diode applied 5 hours before exercise on pain, rate of perceived exertion and maximum voluntary contraction.
4. To determine the difference between light emitting diode applied 5 minutes,1 hour or 5 hours before exercise on pain, rate of perceived exertion and maximum voluntary contraction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Fatigue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5 minutes before 1

Light emitting diode applied 5 minutes before fatiguing task

Group Type EXPERIMENTAL

Light emitting diode

Intervention Type DEVICE

Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

5 minutes before 2

Light emitting diode applied 5 minutes before fatiguing task

Group Type PLACEBO_COMPARATOR

Light emitting diode

Intervention Type DEVICE

Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

1 hour before 1

Light emitting diode applied 1 hour before fatiguing task

Group Type EXPERIMENTAL

Light emitting diode

Intervention Type DEVICE

Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

1 hour before 2

Light emitting diode applied 1 hour before fatiguing task

Group Type PLACEBO_COMPARATOR

Light emitting diode

Intervention Type DEVICE

Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

5 hours before 1

Light emitting diode applied 5 hours before fatiguing task

Group Type EXPERIMENTAL

Light emitting diode

Intervention Type DEVICE

Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

5 hours before 2

Light emitting diode applied 5 hours before fatiguing task

Group Type PLACEBO_COMPARATOR

Light emitting diode

Intervention Type DEVICE

Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Light emitting diode

Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy non athletics subjects.
* Age ranges from 20-40 years.
* Body mass index is less than 25 kg/m 2

Exclusion Criteria

* Neurological deficit and recent injury to either upper extremity
* non diagnosed pain .
* Contraindications to LED irradiation (such as light hypersensitivity, fluctuating blood pressure, insufficient blood circulation, fever and inflammation of the skin)
* Conditions in which physical exertion is contraindicated (such as cardiovascular deficits, hypertension and respiratory problems)
* Restriction in shoulder or elbow range of motion;
* Neoplasm,
* Rheumatoid,
* Strength training in the past 6 months;
* Previous surgery in the spine or upper extremity;
* Complaints of pain in the shoulder, elbow,wrist, and trunk musculature system;
* Use of dietary supplements; and not in any other exercise program for at least the past 3 months.
Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

HAhmed

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Physical Therapy

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P.T.REC/012/002480

Identifier Type: -

Identifier Source: org_study_id